Conferencia de resultados del T2 de 2026 de Protalix BioTherapeutics (PLX): Elfabrio impulsa el crecimiento de los ingresos

Puntos clave

• Protalix BioTherapeutics registró unos ingresos de 19,9 millones de dólares en el segundo trimestre de 2026, un 26,8% más que los 15,7 millones de dólares del segundo trimestre de 2025, lo que refleja principalmente un incremento de las ventas a Chiesi.
• El beneficio neto del segundo trimestre aumentó a 3,8 millones de dólares, o 0,05 dólares por acción básica y diluida, frente a los 164.000 dólares, o 0,00 dólares por acción, del año anterior.
• Los ingresos del primer semestre alcanzaron los 53,6 millones de dólares frente a los 25,8 millones del mismo periodo del año anterior, impulsados por el crecimiento de Elfabrio y el hito de 25 millones de dólares de Chiesi reconocido en el primer trimestre de 2026.
• El efectivo, los equivalentes de efectivo y los depósitos bancarios a corto plazo sumaron 40,7 millones de dólares al 30 de junio de 2026. Protalix no tenía deuda ni warrants pendientes.
• La dirección reafirmó sus previsiones de ingresos para todo el año 2026, al tiempo que advirtió de que los pedidos de los socios y la calendarización de los envíos pueden generar volatilidad trimestral.
• El estudio de Fase 2 RELEASE para el PRX-115 avanza según lo previsto. La dirección prevé que el reclutamiento se complete a finales de 2026 y que los resultados principales estén disponibles en la segunda mitad de 2027.

Datos financieros clave

Los ingresos del primer semestre de 2026 fueron de 53,6 millones de dólares, frente a los 25,8 millones del primer semestre de 2025. Los ingresos por venta de productos sumaron 27,2 millones de dólares frente a 25,4 millones de dólares.

Desempeño comercial y operativo

Elfabrio siguió siendo el principal impulsor del crecimiento comercial a través de la alianza de Protalix con Chiesi. La dirección señaló que las compras del segundo trimestre reflejaron tanto el crecimiento subyacente del negocio como la gestión de inventario de Chiesi. Por ello, la empresa considera que el rendimiento del ejercicio completo resulta más representativo que el de trimestres aislados.

La dirección afirmó que la reciente aprobación de Elfabrio en Europa para la dosificación cada cuatro semanas refuerza su posicionamiento comercial. La empresa citó un mercado global estimado para la enfermedad de Fabry de aproximadamente 3.200 millones de dólares para 2031 y señaló que prevé que Elfabrio podría capturar entre el 15% y el 20% de dicho mercado.

El PRX-115, el candidato a uricasa de acción prolongada de Protalix para la gota no controlada, continúa avanzando en el estudio de Fase 2 de dosis múltiples RELEASE. La dirección indicó que casi todos los centros clínicos previstos habían sido activados, quedando potencialmente solo uno pendiente.

Previsiones de la dirección

Protalix mantuvo sus previsiones de ingresos para todo el año 2026, aunque durante la conferencia de resultados no se especificó el rango de la orientación. La dirección señaló que las tendencias positivas de ingresos y la continuada expansión de Elfabrio respaldan las perspectivas.

La empresa prevé concluir la inclusión de pacientes en el estudio RELEASE a finales de 2026, sujeto a la ejecución del mismo, y anticipa resultados principales en la segunda mitad de 2027.

Se prevé que el gasto en I+D aumente a medida que avance RELEASE y progresen otros programas preclínicos y clínicos. La dirección también espera que la subvención disponible en virtud de la nueva ley de I+D continúe estando accesible de forma continuada.

Riesgos y factores a vigilar

• Los ingresos pueden fluctuar entre trimestres debido a la programación de pedidos de los socios, los calendarios de envío y la gestión de inventario.
• La selección del régimen para la Fase 3 del PRX-115 dependerá de la totalidad de los resultados de la Fase 2, incluyendo eficacia, inmunogenicidad, anticuerpos antidroga y reacciones asociadas a la infusión.
• La dirección indicó que es demasiado pronto para determinar si el régimen preferido priorizará la dosificación cada cuatro semanas sin metotrexato o cada ocho semanas con metotrexato.
• El objetivo de completar el reclutamiento a finales de 2026 sigue estando sujeto a la ejecución del estudio.
• Se prevé que una mayor actividad clínica incremente los gastos de I+D a lo largo del tiempo.

Puntos destacados del turno de preguntas de los analistas

Los analistas se centraron en cómo seleccionará Protalix el régimen de PRX-115 para la Fase 3. La dirección señaló que la decisión considerará aspectos más allá de las tasas de respuesta o la frecuencia de dosificación. La inmunogenicidad, los anticuerpos antidroga, las reacciones asociadas a la infusión y la posibilidad de evitar el metotrexato también influirán en la elección.

Respecto a la dosis fija de 36 miligramos de PRX-115, la dirección afirmó que se seleccionó utilizando datos farmacocinéticos y farmacodinámicos de Fase 1. Se espera que el estudio en curso de dosis múltiples de Fase 2 aporte una visión más clara de las respuestas de anticuerpos antidroga en las distintas ramas de tratamiento.

En cuanto a las pautas de compra de Elfabrio, la dirección atribuyó el sólido nivel de pedidos del segundo trimestre en parte a la planificación de inventario de Chiesi en los distintos mercados y a los requisitos de fabricación. Reiteró que los pedidos trimestrales no deben evaluarse de forma aislada.

La dirección también señaló que los ingresos del líder del mercado actual en gota no controlada fueron de 1.300 millones de dólares en 2025 y muestran una tendencia hacia los 1.600 millones de dólares, lo que calificó de alentador para el PRX-115.

Transcripción completa de la conferencia de resultados

Transcripción completa de la conferencia de resultados

Comentarios de la dirección

Operator

Good morning, ladies and gentlemen, and welcome to the Protalix BioTherapeutics Second Quarter 2026 Financial and Business Results Conference Call. As a reminder, this conference is being recorded. I will now turn the conference over to your host, Mr. Mike Moyer of LifeSci Advisors, Investor Relations for Protalix. Please go ahead.

Mike Moyer

Thank you, operator, and welcome to the Protalix BioTherapeutics Q2 2026 Financial Results and Business Update Conference Call. With me today are Dror Bashan, President and CEO; and Gilad Mamlok, Senior Vice President and Chief Financial Officer. Press release announcing the financial results and corporate updates was issued this morning and is available now on the Protalix website. Please take a moment to read the disclaimer about forward-looking statements in the press release. The earnings release and this teleconference include forward-looking statements. These forward-looking statements are subject to known and unknown risks and uncertainties that may cause actual results to differ materially from the statements made. Factors that could cause actual results to differ are described in the disclaimer and in Protalix' filings with the U.S. Securities and Exchange Commission. I will now turn the call over to Mr. Bashan. Dror?

Dror Bashan

Thank you, Mike, and thank you, everyone, for joining this morning. Our results today reflect the strength of our profitable commercial partnerships, and we remain confident in our outlook for this year. We entered the second half of 2026 with Elfabrio sales through Chiesi continuing to drive growth of our business. Gilad will walk through the financial details, but the key driver in the first half was continued growth in Elfabrio's revenues, together with the previously reported $25 million Chiesi milestone payment recognized in the first quarter of this year. Elfabrio sales through Chiesi continue to drive revenues from selling, and this performance reflects further global penetration of Elfabrio and continued growth. This continued growth keeps us on track with our full year 2026 revenue guidance with the global Fabry market projected to reach approximately $3.2 billion by 2031, Elfabrio is positioned to capture 15% to 20% of this market, supported by our partnership with Chiesi, which is strengthened by the recent approval of the once every 4 weeks dosing regimen in Europe. We believe our revenue mix, particularly the continued expansion of Elfabrio position us well for sustained long-term value creation and [ profitability ].

On the clinical side, PRX-115 continues to advance as planned. PRX-115 is designed as a long-acting differentiated uricase, and we believe it has the potential to meaningfully improve quality of life for patients with uncontrolled gout, which could be a significant inflection point and revenue driver for Protalix. There is a significant unmet need in this population, and we expect top line results from our RELEASE study in the second half of 2027. Beyond PRX-115, our strategy remains centered on rare renal diseases, where we believe our capabilities and platform offer a clear advantage, and we remain focused on execution across our partnerships and pipeline, and we believe our business model limits downside risks while preserving meaningful upside as we advance our clinical programs. With that, I will turn the call over to Gilad for a detailed review of our financial results and outlook. Gilad, please.

Gilad Mamlok

Thank you, Dror. For the second quarter of 2026, total revenues were $19.9 million compared to $15.7 million in the second quarter of 2025. For the first half of 2026, total revenues were $53.6 million compared to $25.8 million for the first half of 2025. For the second quarter of 2026, revenues from selling goods were $19.8 million compared to $15.4 million in the second quarter of 2025, an increase of $4.4 million. For the first half of 2026, revenues from selling goods were $27.2 million compared to $25.4 million for the first half of 2025, an increase of $1.8 million. The increase was driven mainly by higher sales to Chiesi. For the remainder of the results, I will report only on the second quarter, and you can refer to this morning's press release for additional year-to-date. Cost of revenues were $7.8 million compared to $5.9 million in the same period in 2025, an increase of $1.9 million. The increase was mainly attributable to higher sales volumes to Chiesi [indiscernible] and partially offset by lower sales to Pfizer. R&D expenses were $4.4 million, down from $6 million in the prior year period, a decrease of $1.6 million. The decrease was mainly driven by a $2.1 million recorded under the new R&D law as a reduction of R&D expenses. As of 2026, this grant is available for us under the R&D law on an ongoing basis. We expect to continue to incur expenses as the RELEASE study progresses and additional preclinical and clinical programs. G&A expenses were $3.1 million, up $0.5 million from the prior year period, largely attributable to higher salary and related expenses. Finance income net was $0.2 million compared to financial expenses net of $0.5 million in the second quarter of 2025. The change was mainly due to exchange rate fluctuations. Taxes on income were $1.1 million compared to $0.5 million in the second quarter of 2025, an increase of $0.6 million. This increase resulted mainly from taxes on income derived from global intangible low tax income or GILTI resulting from limitations under IRC Section 174. Net income for the quarter was $3.8 million or $0.05 per share basic and diluted compared to net income of $164,000 or $0 per share basic and diluted in the second quarter of 2025. Turning to the balance sheet, cash, cash equivalents and short-term bank deposits totaled $40.7 million as of June 30, 2026. We have no outstanding debt or warrants, providing us with substantial financial flexibility to support our continued pipeline advancements. As we have noted in prior quarters, our revenues can vary from quarter-to-quarter based on the timing of shipments and orders from our partners. We believe it is more useful to evaluate our business on a full year basis, and we remain confident in our full year 2026 guidance. With that, I will turn the call back over to Dror.

Dror Bashan

Thank you, Gilad. In closing, positive revenue trends keeps us firmly on track to meet our full year 2026 guidance. We have a strong cash position to maintain our operations and advance our clinical and preclinical assets. We are confident in the momentum behind our business and about the opportunities ahead. Now I will ask the operator to open the line for questions.

Operator

[Operator Instructions] And our first question -- our first question will come from Raghuram Selvaraju with H.C. Wainwright.

Preguntas y respuestas

Unknown Analyst

This is [ Yuan Zhi ] sitting in for Ram Selvaraju. I have 2. The first is, so your presentation highlights E4W without methotrexate and the E8W with MTX as the 2 differentiated profiles within RELEASE. What totality of evidence framework will determine which regimen advances to Phase 3? And could a modest month 6 responder rate difference be outweighed by eliminating MTX or extending dosing to E8W?

Dror Bashan

I repeat the question? Actually, both. I mean if you manage to 1 of the 5 [indiscernible] without methotrexate [indiscernible], which can be a huge competitive edge, but also a lower frequency of using the drug is also a big advantage, and we potentially can have both.

Unknown Analyst

Right. Okay. So yes, I'll repeat the question. It's -- my question is what totality of evidence will determine which regimen advances to Phase 3? And could a modest month 6 responder rate difference be outweighed by eliminating the methotrexate or extending dosing to every 8 weeks?

Dror Bashan

We are running now the multiple dose study on the Phase 2. We have to see the outcome. And by the outcome, we can decide with which regimens we continue. It's difficult to tell you today. I mean, under what we have from the mechanism of action and the data from the Phase 1 and whatever we understand about the molecule and the PEGylation of the molecule and the outcomes we have so far, we think that these 4 arms, I'm not speaking about the placebo could be met, which one will be met better. We have to consider there is an immunogenicity aspect, there is an IRR aspect. So it's not just the frequency. But let's say, under the assumption immunogenicity is good or low or whatever the definition is and with a pretty low IRR. And then it's only about the frequency and/or with or without methotrexate. We have to see.

Unknown Analyst

Got it. Understood. The other question I have is relating to the 10-K, which reports approximately about 50% of Phase 1 subjects who have developed ADAs and that comes with lower incidence at higher doses. My question is, how does the combined PK, PD and immunogenicity data support selecting that fixed 36-milligram dose? And what ADA profile and RELEASE would support every 4 weeks dosing without methotrexate?

Dror Bashan

So we will -- in Phase 2, we will have the, I would say, the ADA against the enzyme. So we have, I think, a clearer picture of the different ADAs and how -- and what are the outcomes, of course, the different arms. So then we'll see where we are. Don't forget the Phase 2 is the multiple dose. Phase 1 was a single ascending dose chose 36-milligram according to one, I would say, the PK, PD, if I may say, of course, and also under the assumption that this specific, I would say, regimen could be the highest or the more, I would say, convenient and by the way, for the patients, if I may say, both once in 4 weeks without methotrexate and the once in 8 weeks with methotrexate, which call them like the highest outcomes if possible.

Operator

Our next question will come from John Vandermosten with Zacks SCR.

John Vandermosten

Great. Nice to hear from you guys. And congratulations on Elfabrio's patent term extension and the approval in South Korea. Things are going pretty good for that product. I want to start out with a question on just the trend in purchases of Elfabrio. I'm wondering, is there any benefit to having lumpy purchases because we had a nice increase this quarter. And I'm wondering, is that due perhaps to the new approvals in certain geographies? Or is there some other reason in terms of like product runs or some other reason why it makes sense to have lumpy rather than steady purchases of Elfabrio?

Gilad Mamlok

John, thank you. As we always say, one quarter, we prefer to look at the picture always year-to-date. We did have a nice quarter from Chiesi, which reflects also their growth of the business, but mainly reflects their inventory management.

John Vandermosten

Okay. So there's no -- I mean, there's no rationale behind why they wouldn't make it smooth rather than lumpy.

Dror Bashan

This is not a fair definition, I would say. They operate with a lot of sense and logic, of course, and they are responsible for what they are doing. They have their own -- they see the demand. They know how much they sit on certain amount of inventories globally or continent. And of course, their manufacturing plant vis-a-vis other programs that are marketing with a big company. So all in all, this is how it was decided and applied. And of course, to make sure we sit on enough stocks, both [ DS and DP ].

John Vandermosten

Okay. And jumping to 115, I believe you've opened up some new sites or at least on ClinicalTrials.gov, it seems like there are a number of sites listed there compared to previous -- early in the year. How is that going in terms of site activation? And kind of where are you right now? How much can you tell me? And then how many more do you think might be opening in the future so far in 2026?

Dror Bashan

We have actually maybe one site is missing. That's it. And we -- at present, we expect to finalize enrollment within the next 5 months, I mean by year-end as we planned. We'll have to see if things indeed will go this way. So far, so good, knock on wood. That's it. I think overall, except one site that maybe is missing, we are actually signed on whatever we plan to course.

John Vandermosten

And last question is on kind of a bigger picture question on Amgen. They raised price pretty significantly this year, first quarter and second quarter saw 20-plus percent price increases on Krystexxa. And I'm wondering what does that tell you about the market? Does it make it look more attractive? I'm not sure of the details. Perhaps it was a payer mix or something like that. I didn't get into that. But I'm just wondering if you have any thoughts on what that dramatic price increase means for the space.

Dror Bashan

I don't have any insights on that. And I don't know, you get it from what they say or you get it from calculating sales to estimate the number of patients or...

John Vandermosten

It was in the press release or second quarter press release, they said 23% increase in and pricing, even the volumes were down. And they didn't go into it, but I mean, my thought was there's -- the market will accept a higher price, which may make it look more attractive for you guys for 115. So I just wanted to see if that had any impact on your thoughts for this product and the pathway forward.

Gilad Mamlok

The revenues keep growing. It was $1.3 billion in 2025. We see now the trend going to $1.6 billion. So it's very encouraging for 115 as well, as we said.

Operator

And this now concludes our question-and-answer session. I would like to turn the floor back over to Dror Bashan for closing comments.

Dror Bashan

Thank you. So I just like to thank everybody that joined our call, and we look forward to report on our Q3 results as well. I think overall, we have a good strong cash position to maintain our operations and advance our clinical and preclinical assets. And again, we are confident in the momentum behind our business and about the opportunities ahead. So thank you very much.

Operator

Ladies and gentlemen, thank you for your participation. This does conclude today's teleconference. You may disconnect your lines, and have a wonderful day.